Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: J05AX09

Celsentri(maraviroc)

HIV Infections

Marketing Authorisation Holder: ViiV Healthcare B.V.

EMA Authorisation: 18/09/2007

INN: maraviroc

Indication

Celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Celsentri — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.